Bleeding Tolerance Among Patients With Atrial Fibrillation on Oral Anticoagulation
- 1 April 2020
- journal article
- research article
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 36 (4) , 500-508
Abstract
No abstract availableKeywords
Funding Information
- Uniwersytet Jagielloński Collegium Medicum
This publication has 26 references indexed in Scilit:
- Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryAmerican Heart Journal, 2014
- A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillationEuropean Heart Journal, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Apixaban in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Pharmacogenetics of Oral AnticoagulantsClinical Pharmacokinetics, 2008
- Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2007
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Combined Anticoagulant–Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation PatientsStroke, 2004
- Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational studyCommentary: Varied preferences reflect the reality of clinical practiceBMJ, 2001